ASP Isotopes Inc. NASDAQ: ASPI provided a business update, including a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the U.S. The supply contract for silicon-28 is the largest to date, with deliveries expected in Q1 2026. Enriched silicon-28 is crucial for quantum computing and advanced semiconductor development. The acquisition of the radiopharmacy in Florida aligns with PET Labs’ strategy to expand globally and offer PET services from 2027. This move is expected to boost revenues and profits. The Company aims to build a radiopharmacy network for the production of radioisotopes.

The Company is focused on developing technology for isotope production in various industries. Enriched silicon-28 is in high demand for quantum computing, while other isotopes like Molybdenum-100 and Zinc-68 have emerging healthcare applications. The acquisition of the radiopharmacy in Florida is part of the Company’s strategy to expand PET Labs globally and become a leader in radioisotope production for oncology treatment. The Company’s Aerodynamic Separation Process (ASP technology) is ideal for enriching isotopes of low and heavy atomic mass molecules.

Read more at GlobeNewswire: ASP Isotopes Provides Business Updates